```
=> e chain benjamin/au
E1          447     CHAIN B M/AU
E2            5     CHAIN B M */AU
E3           51 --> CHAIN BENJAMIN/AU
E4          146     CHAIN BENJAMIN M/AU
E5            2     CHAIN BENJAMIN MICHAEL/AU
E6            7     CHAIN BENNY/AU
E7            1     CHAIN BM/AU
E8            2     CHAIN BRENT/AU
E9            9     CHAIN C/AU
E10           1     CHAIN C H/AU
E11           9     CHAIN C Y/AU
E12           2     CHAIN CASTRO T DE J/AU

=> s e1-e5 and (chimeric peptid?)
L1            2 ("CHAIN B M"/AU OR "CHAIN B M *"/AU OR "CHAIN BENJAMIN"/AU OR
                "CHAIN BENJAMIN M"/AU OR "CHAIN BENJAMIN MICHAEL"/AU) AND (CHIME
               RIC PEPTID?)

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2            2 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y


L2   ANSWER 1 OF 2  USPATFULL on STN
AN     2006:104446  USPATFULL
TI     Chimeric peptides as immunogens, antibodies thereto,
       and methods for immunization using chimeric peptides
       or antibodies
IN     Chain, Benjamin, London, UNITED KINGDOM
PI     US 2006088548      A1   20060427
AI     US 2000-731899     A1   20001208 (9)
PRAI   US 1999-169687P     19991208 (60)
DT     Utility
FS     APPLICATION
LREP   DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN   Number of Claims: 20
ECL    Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides a chimeric peptide or mixture
       of chimeric peptides that can be formulated as an
       immunizing composition and used in a method for immunization of a mammal
       against an internal peptide cleavage product derived from a precursor or
       mature protein, for which the peptide cleavage product and the precursor
       or mature protein are self molecules. The chimeric
       peptide or peptides have an end-specific B cell epitope from a
       naturally-occurring internal peptide cleavage product of a precursor or
       mature protein, as a free N- or C-terminus, fused with or without spacer
       residues to a T helper cell epitope derived from a living source
       different from that of the internal peptide cleavage product.

L2   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2001:435132  CAPLUS
DN   135:60157
TI   Chimeric peptides as immunogens, antibodies thereto,
     and methods for immunization using chimeric peptides
     or antibodies
IN   Chain, Benjamin
PA   Mindset Biopharmaceuticals (Usa), Inc., USA
```

SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042306	A2	20010614	WO 2000-US33203	20001208
	WO 2001042306	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2393763	AA	20010614	CA 2000-2393763	20001208
	AU 2001027256	A5	20010618	AU 2001-27256	20001208
	AU 784925	B2	20060727		
	EP 1237930	A2	20020911	EP 2000-990195	20001208
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003516419	T2	20030513	JP 2001-543601	20001208
	US 2006088548	A1	20060427	US 2000-731899	20001208
	ZA 2002005032	A	20030922	ZA 2002-5032	20020621
PRAI	US 1999-169687P	P	19991208		
	WO 2000-US33203	W	20001208		

AB The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self mols. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C- terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product. The internal peptide cleavage product is an amyloid β peptide derived from cleavage of β amyloid precursor protein (βAPP); and the chimeric peptide of T helper cell epitope is derived from tetanus toxoid, pertussis toxin, diphtheria toxin, measles virus F protein, etc. Antibodies or monoclonal antibodies raised with the chimeric peptides are useful for passive immunotherapy of diseases such as Alzheimer's disease.

```
=> s (chimeric peptide?) and (T helper cell epitope?) and amyloid
L3            7 (CHIMERIC PEPTIDE?) AND (T HELPER CELL EPITOPE?) AND AMYLOID

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             7 DUP REM L3 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L4   ANSWER 1 OF 7  USPATFULL on STN
AN     2006:104446  USPATFULL
TI     Chimeric peptides as immunogens, antibodies thereto,
       and methods for immunization using chimeric peptides
       or antibodies
```

IN Chain, Benjamin, London, UNITED KINGDOM
PI US 2006088548 A1 20060427
AI US 2000-731899 A1 20001208 (9)
PRAI US 1999-169687P 19991208 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product.

L4 ANSWER 2 OF 7 USPATFULL on STN
AN 2005:188836 USPATFULL
TI Novel method for down-regulation of amyloid
IN Rasmussen, Peter Birk, Horsholm, DENMARK
Jensen, Martin Roland, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
Koefoed, Peter, Horsholm, DENMARK
Degan, Florence Dal, Horsholm, DENMARK
PI US 2005163744 A1 20050728
AI US 2004-783317 A1 20040220 (10)
RLI Continuation-in-part of Ser. No. WO 2002-DK547, filed on 20 Aug 2002, UNKNOWN
PRAI DK 2001-1231 20010820
DK 2002-558 20020416
US 2001-337543P 20011022 (60)
US 2002-373027P 20020416 (60)
DT Utility
FS APPLICATION
LREP FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous APP or Aβ, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or Aβ and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and

pharmaceutical formulations.

L4 ANSWER 3 OF 7 USPATFULL on STN
AN 2005:69661 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, UNITED STATES
Bard, Frederique, Pacifica, CA, UNITED STATES
Yednock, Theodore, Forest Knolls, CA, UNITED STATES
PA Neuralab Ltd (U.S. corporation)
PI US 2005059802 A1 20050317
AI US 2004-777792 A1 20040211 (10)
RLI Continuation of Ser. No. US 2000-723544, filed on 28 Nov 2000, ABANDONED Continuation of Ser. No. US 2000-580018, filed on 26 May 2000, GRANTED, Pat. No. US 6761888 Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999, PENDING Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998, GRANTED, Pat. No. US 6787523
PRAI US 1998-80970P 19980407 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 51
ECL Exemplary Claim: CLM-01-68
DRWN 18 Drawing Page(s)
LN.CNT 4942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.

L4 ANSWER 4 OF 7 USPATFULL on STN
AN 2004:313942 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease
IN Wang, Chang Yi, Harbor, NY, UNITED STATES
PI US 2004247612 A1 20041209
AI US 2004-861614 A1 20040604 (10)
RLI Division of Ser. No. US 2001-865294, filed on 25 May 2001, PENDING
DT Utility
FS APPLICATION
LREP MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053
CLMN Number of Claims: 76
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ.sub.1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble Aβ.sub.1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the "soluble Aβ-derived toxins"; and being cross-reactive to the amyloid

plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

L4 ANSWER 5 OF 7 USPATFULL on STN
AN 2003:225306 USPATFULL
TI Novel method for down-regulation of amyloid
IN Rasmussen, Peter Birk, Horsholm, DENMARK
Jensen, Martin Roland, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
Koefoed, Peter, Horsholm, DENMARK
Degan, Florence Dal, Horsholm, DENMARK
PI US 2003157117 A1 20030821
AI US 2002-223809 A1 20020820 (10)
PRAI DK 2001-1231 20010820
DK 2002-58 20020416
US 2001-337543P 20011022 (60)
US 2002-373027P 20020416 (60)
DT Utility
FS APPLICATION
LREP FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 3681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous APP or Aβ, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or Aβ and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

L4 ANSWER 6 OF 7 USPATFULL on STN
AN 2003:99221 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of Altzheimers Disease
IN Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
PI US 2003068325 A1 20030410
US 6906169 B2 20050614
AI US 2001-865294 A1 20010525 (9)
DT Utility
FS APPLICATION
LREP Maria C.H. Lin, Morgan & Finnegan L.L.P, 345 Park Avenue, New York, NY, 10154-0053
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having

multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ.sub.1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble Aβ.sub.1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the "soluble Aβ-derived toxins"; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:435132 CAPLUS
DN 135:60157
TI Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
IN Chain, Benjamin
PA Mindset Biopharmaceuticals (Usa), Inc., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042306	A2	20010614	WO 2000-US33203	20001208
	WO 2001042306	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2393763	AA	20010614	CA 2000-2393763	20001208
	AU 2001027256	A5	20010618	AU 2001-27256	20001208
	AU 784925	B2	20060727		
	EP 1237930	A2	20020911	EP 2000-990195	20001208
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003516419	T2	20030513	JP 2001-543601	20001208
	US 2006088548	A1	20060427	US 2000-731899	20001208
	ZA 2002005032	A	20030922	ZA 2002-5032	20020621
PRAI	US 1999-169687P	P	19991208		
	WO 2000-US33203	W	20001208		

AB The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self mols. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C- terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product. The internal peptide cleavage product is an amyloid β peptide derived from cleavage of β amyloid precursor protein (βAPP); and the chimeric peptide of

T helper cell epitope is derived
from tetanus toxoid, pertussis toxin, diphtheria toxin, measles virus F protein, etc. Antibodies or monoclonal antibodies raised with the chimeric peptides are useful for passive immunotherapy of diseases such as Alzheimer's disease.